Among patients with relapsed or refractory multiple myeloma, Tecvayli (teclistamab-cqyv) monotherapy was associated with a 71 ...
The CEO of ModeX Therapeutics discusses MDX2003, a groundbreaking tetraspecific therapy that promises enhanced efficacy and ...
SOUTH SAN FRANCISCO, Calif. and MONROVIA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel ...
Investigators have discovered the mechanisms underlying a T-cell receptor's immunosuppressive function, according to a study published Nature Immunology, findings that may provide insight into the ...
This is an illustration of how the engineered protein facilitates destruction of latently HIV-infected immune cells. 1) Protein and cells, from left to right: engineered protein with yellow-and-black ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results